调制式电超高温疗法与肿瘤治疗电场治疗胶质母细胞瘤的荟萃分析

Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.

作者信息

Szasz Attila Marcell, Arrojo Alvarez Elisabeth Estefanía, Fiorentini Giammaria, Herold Magdolna, Herold Zoltan, Sarti Donatella, Dank Magdolna

机构信息

Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.

Oncología Radioterápica, Servicios y Unidades Asistenciales, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.

出版信息

Cancers (Basel). 2023 Jan 31;15(3):880. doi: 10.3390/cancers15030880.

BACKGROUND

Glioblastoma is one of the most difficult to treat and most aggressive brain tumors, having a poor survival rate. The use of non-invasive modulated electro-hyperthermia (mEHT) and Tumor Treating Fields (TTF) devices has been introduced in the last few decades, both of which having proven anti-tumor effects.

METHODS

A meta-analysis of randomized and observational studies about mEHT and TTF was conducted.

RESULTS

A total of seven and fourteen studies about mEHT and TTF were included, with a total number of 450 and 1309 cases, respectively. A 42% [95% confidence interval (95% CI): 25-59%] 1-year survival rate was found for mEHT, which was raised to 61% (95% CI: 32-89%) if only the studies conducted after 2008 were investigated. In the case of TTF, 1-year survival was 67% (95% CI: 53-81%). Subgroup analyses revealed that newly diagnosed patients might get extra benefits from the early introduction of the devices (mEHT all studies: 73% vs. 37%, = 0.0021; mEHT studies after 2008: 73% vs. 54%, = 0.4214; TTF studies: 83% vs. 52%, = 0.0083), compared with recurrent glioblastoma.

CONCLUSIONS

Our meta-analysis showed that both mEHT and TTF can improve glioblastoma survival, and the most benefit may be achieved in newly diagnosed cases.

背景

胶质母细胞瘤是最难治疗且侵袭性最强的脑肿瘤之一，生存率很低。在过去几十年中，已引入了非侵入性调制式电超温治疗（mEHT）和肿瘤电场治疗（TTF）设备，这两种设备均已证明具有抗肿瘤作用。

方法

对关于mEHT和TTF的随机和观察性研究进行了荟萃分析。

结果

分别纳入了7项和14项关于mEHT和TTF的研究，病例总数分别为450例和1309例。发现mEHT的1年生存率为42%[95%置信区间（95%CI）：25 - 59%]，如果仅调查2008年后进行的研究，该生存率提高到61%（95%CI：32 - 89%）。对于TTF，1年生存率为67%（95%CI：53 - 81%）。亚组分析显示，与复发性胶质母细胞瘤相比，新诊断患者可能会从早期引入这些设备中获得额外益处（mEHT所有研究：73%对37%，P = 0.0021；2008年后的mEHT研究：73%对54%，P = 0.4214；TTF研究：83%对52%，P = 0.0083）。